Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation

Cancer Research

Volumn 62, Issue 21, 2002, Pages 6329-6336

  Gschwind, Andreas ^a   Prenzel, Norbert ^a   Ullrich, Axel ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BATIMASTAT; BRADYKININ; CARBACHOL; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; THROMBIN; TYRPHOSTIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSACTIVATION;

CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL MOVEMENT; DNA, NEOPLASM; ENZYME INHIBITORS; GTP-BINDING PROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; LYSOPHOSPHOLIPIDS; MAP KINASE SIGNALING SYSTEM; METALLOENDOPEPTIDASES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; S PHASE; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0036828287     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Gutkind, J. S. Cell growth control by G protein-coupled receptors: From signal transduction to signal integration. Oncogene, 17: 1331-1342, 1998.
2. Kranenburg, O., and Moolenaar, W. H. Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene, 20: 1540-1546, 2001.
3. Fishman, D. A., Liu, Y., Ellerbroek, S. M., and Stack, M. S. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res., 61: 3194-3199, 2001.
4. Xu, Y., Shen, Z., Wiper, D. W., Wu, M., Morton, R. E., Elson, P., Kennedy, A. W., Belinson, J., Markman, M., and Casey, G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA, 280: 719-723, 1998.
5. Gschwind, A., Zwick, E., Prenzel, N., Leserer, M., and Ullrich, A. Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene, 20: 1594-1600, 2001.
6. Kalmes, A., Vesti, B. R., Daum, G., Abraham, J. A., and Clowes, A. W. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ. Res., 87: 92-98, 2000.
7. Daub, H., Wallasch, C., Lankenau, A., Herrlich, A., and Ullrich, A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J., 16: 7032-7044, 1997.
8. Daub, H., Weiss, F. U., Wallasch, C., and Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature (Lond.), 379: 557-560, 1996.
9. 1 for cell cycle progression induced by bombesin and bradykinin. Am. J. Physiol. Cell Physiol., 281: C886-C898, 2001.
10. Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., and Ullrich, A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature (Lond.), 402: 884-888, 1999.
11. Bancroft, C. C., Chen, Z., Yeh, J., Sunwoo, J. B., Yeh, N. T., Jackson, S., Jackson, C., and Van Waes, C. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma. Int. J. Cancer, 99: 538-548, 2002.
12. Quon, H., Liu, F. F., and Cummings, B. J. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck, 23: 147-159, 2001.
13. Azemar, M., Schmidt, M. Arlt, F., Kennel, P., Brandt, B., Papadimitriou, A., Groner, B., and Wels, W. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int. J. Cancer, 86: 269-275, 2000.
14. Albanell, J., Codony-Servat, J., Rojo, F., Del Campo, J. M., Sauleda, S., Anido, J., Raspall, G., Giralt, J., Rosello, J., Nicholson, R. I., Mendelsohn, J., and Baselga, J. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res., 61: 6500-6510, 2001.
15. O-charoenrat, P., Rhys-Evans, P., Modjtahedi, H., Court, W., Box, G., and Eccles, S. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int. J. Cancer, 86: 307-317, 2000.
16. Prenzel, N., Fischer, O. M., Streit, S., Hart, S., and Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer. 8: 11-31, 2001.
17. Chen, Y., Grall, D., Salcini, A. E., Pelicci, P. G., Pouyssegur, J., and Van Obberghen-Schilling, E. Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein-coupled thrombin receptor. EMBO J., 15: 1037-1044, 1996.
18. 2+/calmodulin-dependent transactivation of epidermal growth factor receptor. Circ. Res., 82: 1338-1348, 1998.
19. O-charoenrat, P., Rhys-Evans, P., and Eccles, S. Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells. Int. J, Cancer, 88: 759-765, 2000.
20. O-charoenrat, P., Modjtahedi, H., Rhys-Evans, P., Court, W. J., Box, G. M., and Eccles, S. A. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res., 60: 1121-1128, 2000.
21. Wu, Y., Palad, A. J., Wasilenko, W. J., Blackmore, P. F., Pincus, W. A., Schechter, G. L., Spoonster, J. R., Kohn, E. C., and Somers, K. D. Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole. Clin. Cancer Res., 3: 1915-1921, 1997.
22. Liu, Y., Gilcrease, M. Z., Henderson, Y., Yuan, X. H., Clayman, G. L., and Chen, Z. Expression of protease-activated receptor 1 in oral squamous cell carcinoma. Cancer Lett., 169: 173-180, 2001.
23. Bei, R. Pompa, G., Vitolo, D., Moriconi, E., Ciocci, L., Quaranta, M., Frati, L., Kraus, M. H., and Muraro, R. Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J, Pathol., 195: 343-348, 2001.
24. Eguchi, S., Dempsey, P. J., Frank, G. D., Motley, E. D., and Inagami, T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J. Biol. Chem., 276: 7957-7962, 2001.
25. Filardo, E. J., Quinn, J. A., Bland, K. I., and Frackelton, A, R., Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol., 14: 1649-1660, 2000.
26. Tokumaru, S., Higashiyama, S., Endo, T., Nakagawa, T., Miyagawa, J. I., Yamamori, K., Hanakawa, Y., Ohmoto, H., Yoshino, K., Shirakata, Y., Matsuzawa, Y., Hashimoto, K., and Taniguchi, N. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J. Cell Biol., 151: 209-220, 2000.